Tenaya Therapeutics (NASDAQ:TNYA – Get Free Report) and Sutro Biopharma (NASDAQ:STRO – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk and analyst recommendations.
Earnings & Valuation
This table compares Tenaya Therapeutics and Sutro Biopharma”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tenaya Therapeutics | $1.33 million | 68.60 | -$90.60 million | ($0.53) | -0.77 |
| Sutro Biopharma | $102.48 million | 1.85 | -$191.09 million | ($11.97) | -0.96 |
Tenaya Therapeutics has higher earnings, but lower revenue than Sutro Biopharma. Sutro Biopharma is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Tenaya Therapeutics and Sutro Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tenaya Therapeutics | N/A | -83.75% | -66.53% |
| Sutro Biopharma | -395.25% | N/A | -88.12% |
Analyst Ratings
This is a summary of recent ratings and price targets for Tenaya Therapeutics and Sutro Biopharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tenaya Therapeutics | 1 | 0 | 5 | 1 | 2.86 |
| Sutro Biopharma | 1 | 0 | 10 | 2 | 3.00 |
Tenaya Therapeutics currently has a consensus target price of $4.00, indicating a potential upside of 879.43%. Sutro Biopharma has a consensus target price of $49.50, indicating a potential upside of 331.94%. Given Tenaya Therapeutics’ higher probable upside, equities research analysts clearly believe Tenaya Therapeutics is more favorable than Sutro Biopharma.
Institutional and Insider Ownership
90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 2.5% of Tenaya Therapeutics shares are held by insiders. Comparatively, 1.8% of Sutro Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
Tenaya Therapeutics has a beta of 2.87, meaning that its share price is 187% more volatile than the S&P 500. Comparatively, Sutro Biopharma has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500.
Summary
Tenaya Therapeutics beats Sutro Biopharma on 9 of the 15 factors compared between the two stocks.
About Tenaya Therapeutics
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
About Sutro Biopharma
Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Receive News & Ratings for Tenaya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenaya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
